2-Amino-3-benzyloxypyridineCAS# 24016-03-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 24016-03-3 | SDF | Download SDF |
| PubChem ID | 90334 | Appearance | Powder |
| Formula | C12H12N2O | M.Wt | 200 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 3-phenylmethoxypyridin-2-amine | ||
| SMILES | C1=CC=C(C=C1)COC2=C(N=CC=C2)N | ||
| Standard InChIKey | NMCBWICNRJLKKM-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C12H12N2O/c13-12-11(7-4-8-14-12)15-9-10-5-2-1-3-6-10/h1-8H,9H2,(H2,13,14) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
2-Amino-3-benzyloxypyridine Dilution Calculator
2-Amino-3-benzyloxypyridine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5 mL | 25 mL | 50 mL | 100 mL | 125 mL |
| 5 mM | 1 mL | 5 mL | 10 mL | 20 mL | 25 mL |
| 10 mM | 0.5 mL | 2.5 mL | 5 mL | 10 mL | 12.5 mL |
| 50 mM | 0.1 mL | 0.5 mL | 1 mL | 2 mL | 2.5 mL |
| 100 mM | 0.05 mL | 0.25 mL | 0.5 mL | 1 mL | 1.25 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Griffithinam
Catalog No.:BCN4744
CAS No.:240122-32-1
- Griffithazanone A
Catalog No.:BCN4813
CAS No.:240122-30-9
- QX 314 bromide
Catalog No.:BCC6889
CAS No.:24003-58-5
- Pyrocatechol monoglucoside
Catalog No.:BCN4667
CAS No.:2400-71-7
- Dehydroepiandrosterone enanthate
Catalog No.:BCC8930
CAS No.:23983-43-9
- 13-Deacetyltaxachitriene A
Catalog No.:BCN7390
CAS No.:239800-99-8
- Tolnaftate
Catalog No.:BCC4869
CAS No.:2398-96-1
- Delta-9-Tetrahydrocannabinolic acid
Catalog No.:BCN8098
CAS No.:23978-85-0
- Meranzin
Catalog No.:BCN5092
CAS No.:23971-42-8
- 4,4'-Bis(5-methyl-2-benzoxazolyl)stilbene
Catalog No.:BCC8657
CAS No.:2397-00-4
- Glochidonol
Catalog No.:BCN5091
CAS No.:23963-54-4
- 5-[(2R)-2-Aminopropyl]-1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-indole-7-carbonitrile (2R,3R)-2,3-dihydroxybutanedioate
Catalog No.:BCN1479
CAS No.:239463-85-5
- Agathadiol diacetate
Catalog No.:BCN5093
CAS No.:24022-13-7
- H-Glu-pNA
Catalog No.:BCC2923
CAS No.:24032-35-7
- Salvicine
Catalog No.:BCN3163
CAS No.:240423-23-8
- Isocurcumenol
Catalog No.:BCN3526
CAS No.:24063-71-6
- 5-Chlorothiophene-2-carboxylic acid
Catalog No.:BCC8745
CAS No.:24065-33-6
- Digiferruginol
Catalog No.:BCN3450
CAS No.:24094-45-9
- 6-Isopentenyloxyisobergapten
Catalog No.:BCC8110
CAS No.:24099-29-4
- Sibiricose A6
Catalog No.:BCN2786
CAS No.:241125-75-7
- Sibiricaxanthone B
Catalog No.:BCN2784
CAS No.:241125-81-5
- Adaphostin
Catalog No.:BCC3890
CAS No.:241127-58-2
- Flupenthixol dihydrochloride
Catalog No.:BCC7851
CAS No.:2413-38-9
- 2-CMDO
Catalog No.:BCC5671
CAS No.:24140-98-5
Rapid identification of ligand-binding sites by using an assignment-free NMR approach.[Pubmed:24171460]
J Med Chem. 2013 Nov 27;56(22):9342-50.
In this study, we developed an assignment-free approach for rapid identification of ligand-binding sites in target proteins by using NMR. With a sophisticated cell-free stable isotope-labeling procedure that introduces (15)N- or (13)C-labels to specific atoms of target proteins, this approach requires only a single series of ligand titrations with labeled targets. Using titration data, ligand-binding sites in the target protein can be identified without time-consuming assignment procedures. We demonstrated the feasibility of this approach by using structurally well-characterized interactions between mitogen-activated protein (MAP) kinase p38alpha and its inhibitor 2-Amino-3-benzyloxypyridine. Furthermore, we confirmed the recently proposed fatty acid binding to p38alpha and confirmed the fatty acid-binding site in the MAP kinase insert region.
Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.[Pubmed:15658855]
J Med Chem. 2005 Jan 27;48(2):414-26.
We describe the structure-guided optimization of the molecular fragments 2-Amino-3-benzyloxypyridine 1 (IC(50) 1.3 mM) and 3-(2-(4-pyridyl)ethyl)indole 2 (IC(50) 35 microM) identified using X-ray crystallographic screening of p38alpha MAP kinase. Using two separate case studies, the article focuses on the key compounds synthesized, the structure-activity relationships and the binding mode observations made during this optimization process, resulting in two potent lead series that demonstrate significant increases in activity. We describe the process of compound elaboration either through the growing out from fragments into adjacent pockets or through the conjoining of overlapping fragments and demonstrate that we have exploited the mobile conserved activation loop, consisting in part of Asp168-Phe169-Gly170 (DFG), to generate significant improvements in potency and kinase selectivity.
